Fig. 1: Reduced glutathione and lactoylglutathione accumulate in NSCLC compared to normal lung tissue.
From: Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
a Relative levels of reduced glutathione (GSH) and oxidized glutathione (GSSG) in extracts from normal mouse lung tissue (Lung), or from tumors arising in LA2 and KP mouse NSCLC models as measured by targeted LCMS (Lung, n = 9; LA2, n = 6; KP, n = 11). b Schematic depicting the reaction catalyzed by glyoxalase I (Glo1) to conjugate methylglyoxal to reduced glutathione (GSH) to produce lactoylglutathione (LGSH). c Relative levels of LGSH in normal mouse lung tissue, LA2 tumors, and KP tumors as assessed by LCMS. Data are normalized to tissue weight and peak area (Lung, n = 9; LA2, n = 6; KP, n = 11). d Quantification of LGSH in normal lung tissue and in KP allografts by LCMS. The allografts had been generated from two independent cell lines that were derived from a KP mouse lung tumor13 (n = 6). e LGSH metabolite levels as determined by LCMS detected in extracts from lung cancer and adjacent non-cancer lung tissue resected from 22 human patients with NSCLC. The LGSH peak area for each paired lung cancer and adjacent non-cancer patient sample is shown in Supplementary Fig. 1e. f Western blot analysis to assess Glo1 expression in normal mouse lung tissue and in KP lung tumors. P values were calculated by unpaired, two-tailed t-test. Values shown in panels a, c, d, and e denote the mean ± SEM.
